PT2042182E - Composição farmacêutica que compreende arsenito para o tratamento de malignidade - Google Patents

Composição farmacêutica que compreende arsenito para o tratamento de malignidade Download PDF

Info

Publication number
PT2042182E
PT2042182E PT81682437T PT08168243T PT2042182E PT 2042182 E PT2042182 E PT 2042182E PT 81682437 T PT81682437 T PT 81682437T PT 08168243 T PT08168243 T PT 08168243T PT 2042182 E PT2042182 E PT 2042182E
Authority
PT
Portugal
Prior art keywords
tumor
treatment
pharmaceutical composition
arsenite
malignancy
Prior art date
Application number
PT81682437T
Other languages
English (en)
Portuguese (pt)
Inventor
Bernardus Rademaker
Original Assignee
Komipharm Int Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29244880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2042182(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Komipharm Int Co Ltd filed Critical Komipharm Int Co Ltd
Publication of PT2042182E publication Critical patent/PT2042182E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT81682437T 2002-04-10 2002-04-10 Composição farmacêutica que compreende arsenito para o tratamento de malignidade PT2042182E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2002/000231 WO2003086424A1 (en) 2002-04-10 2002-04-10 Pharmaceutical composition comprising arsenite for the treatment of malignancy

Publications (1)

Publication Number Publication Date
PT2042182E true PT2042182E (pt) 2013-08-28

Family

ID=29244880

Family Applications (2)

Application Number Title Priority Date Filing Date
PT81682437T PT2042182E (pt) 2002-04-10 2002-04-10 Composição farmacêutica que compreende arsenito para o tratamento de malignidade
PT27229681T PT1496918T (pt) 2002-04-10 2002-04-10 Utilização de meta-arsenito de sódio para o tratamento de tumores

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT27229681T PT1496918T (pt) 2002-04-10 2002-04-10 Utilização de meta-arsenito de sódio para o tratamento de tumores

Country Status (25)

Country Link
US (1) US20050106262A1 (cg-RX-API-DMAC7.html)
EP (2) EP2042182B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005525397A (cg-RX-API-DMAC7.html)
CN (1) CN1298332C (cg-RX-API-DMAC7.html)
AP (1) AP2004003167A0 (cg-RX-API-DMAC7.html)
AU (2) AU2002253713B2 (cg-RX-API-DMAC7.html)
BG (1) BG66356B1 (cg-RX-API-DMAC7.html)
BR (1) BR0215689A (cg-RX-API-DMAC7.html)
CA (1) CA2481602C (cg-RX-API-DMAC7.html)
CY (1) CY1114422T1 (cg-RX-API-DMAC7.html)
DK (2) DK2042182T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP045408A (cg-RX-API-DMAC7.html)
ES (2) ES2425418T3 (cg-RX-API-DMAC7.html)
FI (1) FI1496918T3 (cg-RX-API-DMAC7.html)
HU (1) HU230851B1 (cg-RX-API-DMAC7.html)
IL (2) IL164470A0 (cg-RX-API-DMAC7.html)
LT (1) LT1496918T (cg-RX-API-DMAC7.html)
MX (1) MXPA04009898A (cg-RX-API-DMAC7.html)
NO (1) NO335317B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ536452A (cg-RX-API-DMAC7.html)
PT (2) PT2042182E (cg-RX-API-DMAC7.html)
RO (1) RO123269B1 (cg-RX-API-DMAC7.html)
TN (1) TNSN04198A1 (cg-RX-API-DMAC7.html)
UA (1) UA80426C2 (cg-RX-API-DMAC7.html)
WO (1) WO2003086424A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024492A2 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Medical implant provided with inhibitors of atp synthesis
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
US20100249210A1 (en) * 2008-09-30 2010-09-30 Michael Bastiani Methods and compositions related to dlk-1 and the p38 mapk pathway in nerve regeneration
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
CA2772411C (en) * 2009-09-10 2017-08-22 Kominox, Inc. Cancer stem cell-targeted and drug resistant cancer therapy
EP2477635A4 (en) * 2009-09-18 2013-03-27 Kominox Inc METHODS OF TREATING CEREBRAL TUMORS
CN101695501B (zh) * 2009-10-10 2013-08-14 广汉恒宇新材料有限公司 一种纳米尺寸亚砷酸的壳聚糖包载体及其制造方法
KR102868121B1 (ko) 2018-03-22 2025-10-14 코미팜 인터내셔널 오스트레일리아 피티와이 엘티디 메타 아비산염을 포함하는 약학 조성물 및 제조 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0804928B1 (en) * 1994-02-18 2004-10-20 Tamara Vasilievna Vorobieva Agent having an immunomodulating effect and reducing disturbed functioning of the tissue cell propagation regulating system
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
CN1119152C (zh) * 1998-08-02 2003-08-27 哈尔滨医科大学第一临床医学院 治疗消化系统肿瘤注射液及其应用

Also Published As

Publication number Publication date
DK2042182T3 (da) 2013-08-26
MXPA04009898A (es) 2005-06-20
BR0215689A (pt) 2005-02-01
ES2944907T3 (es) 2023-06-27
EP2042182B1 (en) 2013-05-22
NO335317B1 (no) 2014-11-10
CA2481602A1 (en) 2003-10-23
ECSP045408A (es) 2006-03-01
US20050106262A1 (en) 2005-05-19
CY1114422T1 (el) 2016-08-31
DK1496918T3 (da) 2023-05-15
NZ536452A (en) 2007-06-29
PT1496918T (pt) 2023-05-25
EP1496918B1 (en) 2023-02-08
BG108932A (en) 2005-11-30
BG66356B1 (bg) 2013-09-30
HU230851B1 (en) 2018-09-28
EP2042182A1 (en) 2009-04-01
AU2008255139B2 (en) 2013-10-03
IL164470A (en) 2010-12-30
IL164470A0 (en) 2005-12-18
AU2008255139A1 (en) 2009-01-08
TNSN04198A1 (en) 2007-03-12
RO123269B1 (ro) 2011-05-30
HUP0500199A2 (en) 2007-02-28
WO2003086424A1 (en) 2003-10-23
CN1625407A (zh) 2005-06-08
HUP0500199A3 (en) 2008-03-28
CN1298332C (zh) 2007-02-07
ES2425418T3 (es) 2013-10-15
EP1496918A1 (en) 2005-01-19
JP2005525397A (ja) 2005-08-25
AP2004003167A0 (en) 2004-12-31
AU2002253713B2 (en) 2008-09-18
AU2002253713A1 (en) 2003-10-27
UA80426C2 (en) 2007-09-25
LT1496918T (lt) 2023-05-25
NO20044573L (no) 2004-10-22
CA2481602C (en) 2011-06-21
FI1496918T3 (fi) 2023-05-11

Similar Documents

Publication Publication Date Title
Mohsenikia et al. The protective and therapeutic effects of alpha-solanine on mice breast cancer
EP3356359B1 (en) Inhibitors of kras g12c mutant proteins
Sun et al. AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor activity
Mitsui et al. Antitumor activity of polyoxomolybdate,[NH3Pri] 6 [Mo7O24]· 3H2O, against, human gastric cancer model
AU2008255139A1 (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
Deegan et al. The nephrotoxicity, cytotoxicity and renal handling of a cisplatin-methionine complex in male Wistar rats
KR100456831B1 (ko) 메타아르세나이트을 함유한 항암제 조성물
WO2007098719A1 (es) Combinación farmaceutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
O’Neill et al. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and-resistant human ovarian carcinoma cells
CN114394623A (zh) 一种具有抗肿瘤生物活性的锑钨氧酸盐及其制备方法
EP1043316A2 (en) Nitroimidazole derivatives as sensitivity enhancers for chemotherapy and radiotherapy
JP4571817B2 (ja) 抗菌剤
AU2008258216A1 (en) Pharmaceutical composition comprising arsenite for the treatment of malignancy
Maier et al. The cytotoxic interaction of inorganic trace elements with EDTA and cisplatin in sensitive and resistant human ovarian cancer cells
RU2310460C2 (ru) Фармацевтическая композиция для лечения злокачественной опухоли, содержащая арсенит натрия
Sadeghi Aliabadi et al. Cytotoxicity and antitumor properties of a marine compound on cancer cells (HESA-A)
RU2358721C1 (ru) Антинеопластический препарат (варианты)
ZA200408114B (en) Pharmaceutical compositions comprising arsenite for the treatment of malignancy
US12037309B2 (en) Compound, agent and composition for the suppression of cancer growth
CN103980174B (zh) 取代吡咯烷氨荒酸铋(ⅲ)配合物及其制备方法和在制备抗肿瘤药物中的应用
Bai et al. Novel Oxovanadium Complex VO (hntdtsc)(NPIP): Anticancer Activity and Mechanism of Action on
Andronache et al. USE OF MICROMOLECULAR COPPER COMPLEXES OF THIOSEMICARBAZIDES AS AN EN20D2O0GENOUS CATALASE INDUCER/ACTIVATOR
Vidal-Valenzuela et al. ANTIANGIOGENIC POTENTIAL OF AN ANTHRAQUINONE METABOLITE ISOLATED FROM A MARINE FUNGUS
SINGH et al. Mitochondria as a target for combination cancer-chemotherapy